spacer
home > pmps > summer 2017 > serialisation software
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Serialisation Software

The Falsified Medicines Directive (FMD) deadline of February 2019 is fast approaching for European pharmaceutical manufacturers and their supply chain partners. As the EU Intellectual Property Office discovered in a 2016 study, fake medicines cost the EU pharma industry more than €10 billion in lost revenue and nearly 38,000 lost jobs every year (1). The FMD-mandated measures – which include a unique identifier code and tamper-evident packaging for pharma products – will protect supply chains and help cut down on these losses.

More importantly, the new law provides health and safety benefits. While no definitive findings on the human toll of falsified drugs exist, they are believed to be responsible for 100,000 to 1,000,000 deaths every year, worldwide. Although compliance with FMD is undeniably important, it should not be the only factor driving pharma companies’ serialisation decisions and actions.

Additionally, as more firms integrate Internet of Things technologies into their production and business processes, serialisation presents an opportunity to collect data to create smarter, more efficient supply chains. Pharma manufacturers are realising that they can get a return on their compliance investment by capturing serialisation data and turning them into valuable insights that enhance business operations. Because of this, companies and their partners should be mindful when evaluating and implementing serialisation software to boost visibility, productivity and business optimisation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Michael Howe is Chief Executive Officer at Verify Brand. As a pioneer in creating disruptive innovations, he leverages his decades of experience with Fortune 100 companies and other leading brands to help pharma organisations integrate serialisation technology to drive business growth.
spacer
Michael Howe
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

World-leading cancer stem cell expert joins Avacta Scientific Advisory Board

Developer of biotherapeutics and research reagents announces the appointment of Professor Gerard Evan to its Scientific Advisory Board
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

6th Annual Cancer Vaccines Conference

27-28 September 2017, Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies. SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement